Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine
Vu H. Duong(University of Maryland, Baltimore), Maria R. Baer(University of Maryland, Baltimore), Bhavana Bhatnagar(The Ohio State University), Dan P. Zandberg(University of Pittsburgh Medical Center), Emily J. Vannorsdall(University of Maryland, Baltimore), Qing Chen(Nanjing Drum Tower Hospital), Michael L. Tidwell(University of Maryland, Baltimore)
Cited by 25
Related Papers
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
<i>IDH1</i> and <i>IDH2</i> Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
|Journal of Clinical Oncology|2010|764